Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

OBIO vs CRBP: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OBIO Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 4–4 Matrix Metrics)

OBIO Overall Winner 6-Pillar Tally: OBIO 3 – 2 CRBP (1 Tie) Matrix Metrics: OBIO 4 – 4 CRBP

As of Nov 16, 2026, Orchestra BioMed Holdings, Inc. (OBIO) is the stronger overall head-to-head candidate over Corbus Pharmaceuticals Holdings, Inc. (CRBP) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). OBIO carries a Unified Composite Score of 37.5/100 (SELL) at $7.12 (N/M Forward P/E, -195.4% operating margin), whereas CRBP carries 42.5/100 (HOLD) at $3.38 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While CRBP currently prints a higher short-term Unified Composite Score (42.5/100 HOLD vs. OBIO 37.5/100 SELL), OBIO captures the overall institutional head-to-head verdict (4–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-195.4% vs. 0.0% operating margin) and revenue trajectory (-89.4% vs. -100.0% YoY).
  • Technical & Structure Timing Caution: OBIO trades in a Markup technical trend (BREAKOUT options phase, RSI 69.2); meanwhile CRBP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OBIO vs CRBP
OBIO NASDAQ Head-to-Head Winner
Orchestra BioMed Holdings, Inc. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$7.12
-1.79% 1D
Market Cap $570.6M
TTM Revenue $31M
Forward P/E N/M
Beta / 30D Vol 1.15β · 82% Vol
Unified Composite Score
37.5 / 100 SELL
Tech 15.0 Fund 36.0 Flow 55.0 Mom 44.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.7% over 20 days), RSI 69
RSI-14: 69.2 · SMA20: $5.93 · SMA50: $5.90
CRBP NASDAQ
Corbus Pharmaceuticals Holdings, Inc.
Pharmaceutical Preparations
$3.38
-0.44% 1D
Market Cap $69.9M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.93β · 121% Vol
Unified Composite Score
42.5 / 100 HOLD
Tech 33.0 Fund 56.0 Flow 69.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -32.8%), weak momentum, RSI 34
RSI-14: 34.3 · SMA20: $3.83 · SMA50: $5.51

6-Pillar Scorecard Institutional Category Breakdown (OBIO 3 – 2 CRBP)

Columns: Metric · OBIO · CRBP
1. Valuation Multiples OBIO
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 18.6x N/M
2. Growth & Scale OBIO
Revenue Growth (YoY) -89.4% -100.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $31M N/A
Market Cap $570.6M $69.9M
3. Profitability & Quality CRBP
Gross Margin 99.6% N/A
Operating Margin -195.4% 0.0%
Net Profit Margin -182.5% 0.0%
Return on Equity (ROE) -182.3% -131.5%
4. Balance Sheet & Cash Flow CRBP
Cash Generation (TTM) -$64M -$92M
Cash Flow Margin N/A N/A
Net Cash / Leverage $9.0M Net Debt (4.72x D/E) $26M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning OBIO
Options Structure Phase BREAKOUT BREAKDOWN
Current IV / %ile 70.8% (<1st %ile) 197.6% (66th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OBIO (4) vs CRBP (4)
Institutional Metric OBIO CRBP Criterion Row Edge
Market Capitalization
Scale
$570.6M $69.9M Larger Scale OBIO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-89.4% -100.0% Higher Growth OBIO
Operating Margin (TTM)
Profitability
-195.4% 0.0% Higher Margin CRBP
Net Profit Margin
Profitability
-182.5% 0.0% Higher Margin CRBP
Return on Equity (ROE)
Capital Efficiency
-182.3% -131.5% Higher ROE CRBP
52-Week Range Position
Momentum
92% ($3–$7) 6% ($3–$13) Stronger Trend OBIO
Beta / 30D Volatility
Risk Regime
1.15β · 82% Vol 1.93β · 121% Vol Lower Realized Risk OBIO
Unified Institutional Score
Composite Signal
37.5 / 100 (SELL) 42.5 / 100 (HOLD) Higher Composite CRBP
Trailing 12M Revenue (USD)
Operating Scale
$31M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
99.6% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 18.6x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$64M ($9.0M Net Debt (4.72x D/E)) -$92M ($26M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OBIO +55.97 pp
OBIO: +30.64% · CRBP: -25.33%
3M Horizon OBIO +92.32 pp
OBIO: +25.8% · CRBP: -66.52%
6M Horizon OBIO +144.97 pp
OBIO: +78.89% · CRBP: -66.08%
1Y Horizon OBIO +139.84 pp
OBIO: +70.33% · CRBP: -69.51%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period OBIO Revenue CRBP Revenue OBIO Op. Margin CRBP Op. Margin Margin Leader
FY2018 N/A $0M N/A -1176.8% CRBP
FY2019 N/A $40M N/A -213.3% CRBP
FY2020 N/A $0M N/A -3119.2% CRBP
FY2021 N/A $0M N/A -6350.1% CRBP
FY2022 $0M N/A -924.3% N/A OBIO
FY2023 $0M N/A -1866.2% N/A OBIO
FY2024 $0M N/A -2437.5% N/A OBIO
FY2025 $30M N/A -154.7% N/A OBIO

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OBIO BREAKOUT
32d in phase · OBV ACCUMULATION
Current IV 70.8%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact OBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CRBP BREAKDOWN
58d in phase · OBV NEUTRAL
Current IV 197.6%
IV Percentile 66th %ile
Put/Call OI Skew N/A
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CRBP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $570.6M market capitalization and -195.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CRBP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $69.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ OBIO vs CRBP Key Questions & Quantitative Answers

As of Nov 16, 2026, Orchestra BioMed Holdings, Inc. (OBIO) is the stronger overall head-to-head candidate over Corbus Pharmaceuticals Holdings, Inc. (CRBP) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). OBIO carries a Unified Composite Score of 37.5/100 (SELL) at $7.12 (N/M Forward P/E, -195.4% operating margin), whereas CRBP carries 42.5/100 (HOLD) at $3.38 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While CRBP currently prints a higher short-term Unified Composite Score (42.5/100 HOLD vs. OBIO 37.5/100 SELL), OBIO captures the overall institutional head-to-head verdict (4–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-195.4% vs. 0.0% operating margin) and revenue trajectory (-89.4% vs. -100.0% YoY). Technical & Structure Timing Caution: OBIO trades in a Markup technical trend (BREAKOUT options phase, RSI 69.2); meanwhile CRBP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

OBIO leads the Growth & Scale pillar: OBIO posts -89.4% YoY revenue growth and +0.0% YoY earnings growth on $31M TTM revenue (99.6% gross margin, -195.4% operating margin), compared with CRBP at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), OBIO cumulative revenue shifted N/A while CRBP shifted N/A. In operating R&D and SG&A reinvestment, OBIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CRBP.

OBIO screens cheaper on headline valuation multiples. OBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 18.6x EV/Revenue (unreported FCF margin), whereas CRBP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OBIO (-182.3% ROE) versus CRBP (-131.5% ROE) capital efficiency.

In options market volatility and institutional positioning, OBIO carries 70.8% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.15β · 82% Vol realized risk). By comparison, CRBP carries 197.6% implied volatility (66th %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.93β · 121% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.